Compare Moderna, Inc. (MRNA) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Vale SA — how do they compare? Moderna, Inc. trades at $59.66 (market cap $23.60B), while Vale SA trades at $14.13 (market cap $59.07B). The key difference: Vale SA is far larger — about 2.5× Moderna, Inc.'s market cap, and Vale SA pays a 8.93% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | VALE | |
|---|---|---|
Market Cap | $23.60B | $59.07B |
Sector | Health | Basic Materials |
52-Week High | $81.80 | $17.82 |
52-Week Low | $22.36 | $9.53 |
Enterprise Value | $19.70B | $75.99B |
Dividend Yield | — | 8.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.
Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.
VALE trades at $14.25, up 0.42% today but down 11% over the past month. Technical indicators show a bearish trend with moving averages signaling sell pressure. Fundamentally, revenue declined to $38.4B in 2025 with net income falling to $2.35B, though cash flow improved to $2.42B. Recent news highlights board governance disputes and a $2.6B decarbonization investment announced in June 2026.
The outlook remains cautious with mixed analyst ratings (40.5% buy, 48.7% hold) and a $17.13 consensus target. Risks include volatile iron ore prices and execution challenges, but stable cash flow and low debt provide some resilience. Upside depends on commodity demand recovery and cost management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
